---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026809"
form_type: "8-K"
ticker: null
cik: "0001069308"
company_name: "Acer Therapeutics Inc."
filed_at: "2023-06-07T23:59:59+00:00"
generated_at: "2026-06-14T05:35:26.379507+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acer Therapeutics faces Nasdaq delisting risk from bid price and MVLS deficiencies

## Summary
- Received bid price deficiency notice June 5, 2023; must close at $1.00+ for 10 consecutive business days by Dec 4, 2023.
- Received MVLS deficiency notice May 3, 2023; MVLS must be $35M+ for 10 consecutive business days by Oct 30, 2023.
- May also cure MVLS deficiency by meeting minimum stockholders' equity of $2.5 million.
- If not cured by deadlines, eligible for additional 180-day bid price cure period or delisting appeal.

## SEC filing metadata
- accession: 0000950170-23-026809
- form_type: 8-K
- cik: 0001069308
- company_name: Acer Therapeutics Inc.
- filed_at: 2023-06-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/0000950170-23-026809-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/acer-20230605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026809
- JSON: https://secwatch.observer/filing/0000950170-23-026809.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026809.txt

## Key facts
- Listing & Compliance Notices
  Acer Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: June 5, 2023, Acer Therapeutics Inc. (the “Company”) received a letter (the “Bid Price Deficiency Notice”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Bid Price Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Capital Market under
  evidence_url: https://www.sec.gov/Archives/edgar/data/1069308/000095017023026809/0000950170-23-026809-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.